Eli Lilly's New Pill Beats Wegovy
Eli Lilly's experimental oral drug orforglipron outperformed Novo Nordisk's oral semaglutide (Wegovy) in a head-to-head trial. The GLP-1 pill was more effective at lowering both A1c and body weight in adults with type 2 diabetes over 52 weeks, positioning it as a potential new leader in the oral diabetes drug market.
The key differentiator for Eli Lilly's orforglipron is its formulation as a nonpeptide, small-molecule drug. This structure allows for once-daily oral administration without the food or water timing restrictions required for Novo Nordisk's peptide-based oral semaglutide (Wegovy). This convenience, coupled with potentially simpler and cheaper large-scale manufacturing, could significantly influence patient adherence and market accessibility. In the ACHIEVE-3 head-to-head trial, orforglipron demonstrated superior efficacy. At the highest doses, orforglipron achieved a 2.2% reduction in A1C compared to 1.4% for oral semaglutide. Patients on orforglipron also experienced greater weight loss, averaging 19.7 pounds (a 9.2% reduction), which was 73.6% more than those on semaglutide. Despite the superior efficacy, a higher percentage of trial participants discontinued orforglipron due to adverse events compared to oral semaglutide. Discontinuation rates for orforglipron ranged from 8.7% to 9.7%, while they were between 4.5% and 4.9% for oral semaglutide. Gastrointestinal side effects like nausea and diarrhea were the most common issues reported for both treatments. The oral anti-diabetic drug market is a significant and growing sector, valued at over $45 billion in 2024 and projected to exceed $66 billion by 2034. Analysts project that daily oral obesity pills could capture a $22 billion segment of the global market by 2030, with some predicting Eli Lilly could secure a 60% share of that segment. Some forecasts suggest orforglipron alone could generate up to $12.7 billion in revenue by 2030. Eli Lilly is positioning for a major market entry, having stockpiled $1.5 billion worth of orforglipron in anticipation of regulatory approval. The company has filed for approval in over 40 countries and expects a decision from the U.S. FDA for an obesity indication in the second quarter of 2026. The use of a fast-track review voucher could shorten the FDA's decision timeline significantly. This direct challenge to Novo Nordisk's market dominance has financial implications. Following a series of clinical trial wins for Eli Lilly, including Zepbound outperforming Novo's next-generation candidate CagriSema, Novo Nordisk's shares experienced a significant plunge. In response to the increased competition, Novo Nordisk has signaled plans to reduce the U.S. list prices for its GLP-1 drugs.
